Trajan Scientific and Medical has significantly bolstered its global team, announcing four new appointments that add enviable skills and extensive experience to the organization as it continues to grow and expand around the world.
The appointments point to a strategic migration of the global footprint for Trajan, expanding in key markets such as Asia with the appointment of Takeyoshi Ide as Sales Manager Japan. Mr Ide brings significant expertise not only in chromatography, but also the life science market.
Bridging the gap between the academic world and real life is a major focus for Trajan, as demonstrated by the appointment of Dr Robert (Rob) Shellie as Chromatography Market Manager. Dr Shellie was Associate Professor of Chemistry at the University of Tasmania in Hobart, Australia prior to joining Trajan. With multiple achievements of international recognition Dr Shellie is well experienced at translating chromatography technologies into meaningful applications.
Trajan’s focus is on developing and commercialising technologies that enable analytical systems to be more selective, sensitive and specific for biological, environmental or food related measurements - especially those that can lead to portability, miniaturization and affordability.
The appointment of Dr Pawanbir Singh as Pathology Market Manager from medical device and life science organizations including Leica Biosystems and STEMCELL Technologies, is a tangible demonstration of the strategic importance placed on this focus. Dr Singh pursued a PhD at the Centre for Biological Engineering at Loughborough University where he worked on scale-up and process optimization of regenerative medicine based products, developing an industry investment readiness reference model for these products as part of his doctoral studies.
In other new appointment news, Dr Michelle Carr joins as Commercialization Manager based in Melbourne, Australia. Dr Carr was CEO of Telezon Limited, a technology company focussed on unique processes for polymer injection systems.
Chief Executive Officer of Trajan, Stephen Tomisich comments: "Trajan is proud to be expanding its global team with people who bring complementary experience to the table. We are serious about continuing the growth of our team around the world, all united in fulfilling our passion to develop technologies that will impact human wellbeing."
Trajan Scientific and Medical’s hemaPEN® has been independently evaluated and the results of the study published in the Royal Society of Chemistry’s journal Analyst - selected for the cover of issue 17. hemaPEN demonstrated significant advantages for blood sampling to support better healthcare decision making.
Trajan Scientific and Medical has listed its hemaPEN® blood microsampling device with the U.S. Food and Drug Administration as Class I for therapeutic and in vitro diagnostic use. This follows the hemaPEN’s recent registration in May for supply in the EU and UK as a General IVD; as well as inclusion in the TGA’s ARTG (Australian Register of Therapeutic Goods) in February as a Class I IVD.